Lazard Asset Management’s GSK GSK Stock Holding History

Lazard Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.76M	Buy	49,946 +3,466	+7%	+$188K	﹤0.01%	762
2025 Q4	$2.28M	Buy	46,480 +11,861	+34%	+$553K	﹤0.01%	813
2025 Q3	$1.49M	Sell	34,619 -24,596	-42%	-$961K	﹤0.01%	977
2025 Q2	$2.27M	Sell	59,215 -22,643	-28%	-$865K	﹤0.01%	974
2025 Q1	$3.17M	Buy	81,858 +21,041	+35%	+$770K	﹤0.01%	823
2024 Q4	$2.06M	Sell	60,817 -480	-0.8%	-$17.3K	﹤0.01%	873
2024 Q3	$2.5M	Hold	61,297	–	–	﹤0.01%	823
2024 Q2	$2.36M	Buy	61,297 +5,319	+10%	+$224K	﹤0.01%	828
2024 Q1	$2.4M	Buy	55,978 +27,015	+93%	+$1.11M	﹤0.01%	807
2023 Q4	$1.07M	Buy	28,963 +4,540	+19%	+$163K	﹤0.01%	939
2023 Q3	$885K	Sell	24,423 -7,440	-23%	-$264K	﹤0.01%	1006
2023 Q2	$1.14M	Hold	31,863	–	–	﹤0.01%	968
2023 Q1	$1.13M	Buy	31,863 +5,143	+19%	+$180K	﹤0.01%	1000
2022 Q4	$938K	Hold	26,720	–	–	﹤0.01%	1007
2022 Q3	$786K	Hold	26,720	–	–	﹤0.01%	1025
2022 Q2	$1.45M	Hold	26,720	–	–	﹤0.01%	952
2022 Q1	$1.45M	Hold	26,720	–	–	﹤0.01%	947
2021 Q4	$1.47M	Buy	26,720 +800	+3%	+$41.6K	﹤0.01%	959
2021 Q3	$1.24M	Hold	25,920	–	–	﹤0.01%	1017
2021 Q2	$1.29M	Hold	25,920	–	–	﹤0.01%	913
2021 Q1	$1.16M	Sell	25,920 -2,260	-8%	-$103K	﹤0.01%	883
2020 Q4	$1.3M	Hold	28,180	–	–	﹤0.01%	858
2020 Q3	$1.32M	Buy	28,180 +800	+3%	+$40.1K	﹤0.01%	778
2020 Q2	$1.4M	Sell	27,380 -800	-3%	-$41K	﹤0.01%	721
2020 Q1	$1.33M	Sell	28,180 -2,560	-8%	-$137K	﹤0.01%	712
2019 Q4	$1.8M	Sell	30,740 -471	-2%	-$26.2K	﹤0.01%	680
2019 Q3	$1.67M	Hold	31,211	–	–	﹤0.01%	694
2019 Q2	$1.56M	Hold	31,211	–	–	﹤0.01%	782
2019 Q1	$1.63M	Sell	31,211 -2,208	-7%	-$110K	﹤0.01%	769
2018 Q4	$1.6M	Buy	33,419 +1,600	+5%	+$78.8K	﹤0.01%	664
2018 Q3	$1.6M	Hold	31,819	–	–	﹤0.01%	687
2018 Q2	$1.6M	Hold	31,819	–	–	﹤0.01%	687
2018 Q1	$1.55M	Sell	31,819 -9,418	-23%	-$439K	﹤0.01%	669
2017 Q4	$1.83M	Sell	41,237 -250	-0.6%	-$11.5K	﹤0.01%	642
2017 Q3	$2.1M	Buy	41,487 +385	+0.9%	+$19.5K	﹤0.01%	623
2017 Q2	$2.21M	Buy	41,102 +8,803	+27%	+$469K	﹤0.01%	610
2017 Q1	$1.7M	Sell	32,299 -400	-1%	-$20.3K	﹤0.01%	667
2016 Q4	$1.57M	Sell	32,699 -64,160	-66%	-$3.17M	﹤0.01%	644
2016 Q3	$5.22M	Hold	96,859	–	–	0.01%	508
2016 Q2	$5.25M	Hold	96,859	–	–	0.01%	496
2016 Q1	$4.91M	Sell	96,859 -28	-0%	-$1.4K	0.01%	494
2015 Q4	$4.89M	Buy	96,887 +28	+0%	+$1.43K	0.01%	516
2015 Q3	$4.66M	Hold	96,859	–	–	0.01%	494
2015 Q2	$5.04M	Sell	96,859 -32	-0%	-$1.8K	0.01%	517
2015 Q1	$5.59M	Buy	96,891 +1,232	+1%	+$70.6K	0.01%	512
2014 Q4	$5.11M	Sell	95,659 -49	-0.1%	-$2.74K	0.01%	536
2014 Q3	$5.5M	Sell	95,708 -751	-0.8%	-$46K	0.01%	496
2014 Q2	$6.45M	Sell	96,459 -240	-0.2%	-$16.2K	0.01%	489
2014 Q1	$6.46M	Hold	96,699	–	–	0.01%	446
2013 Q4	$6.45M	Hold	96,699	–	–	0.01%	458
2013 Q3	$6.06M	Sell	96,699 -80	-0.1%	-$5.15K	0.01%	461
2013 Q2	$6.04M	Buy	+96,779	New	+$6.14M	0.01%	471

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Lazard Asset Management's GSK Position: Q1 2026 in Review

Lazard Asset Management increased its GSK (GSK) stake by 7.5% in Q1 2026, buying an estimated $188K and bringing the position to 49,946 shares worth $2.76M. The position accounts for ﹤0.01% of the portfolio, ranked #762.

Lazard Asset Management first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.46M in Q1 2014. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Lazard Asset Management held 49,946 shares of GSK worth $2.76M as of Q1 2026.
Lazard Asset Management bought 3,466 GSK shares in Q1 2026, an estimated $188K.
GSK made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #762 holding.
Lazard Asset Management first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
Lazard Asset Management's GSK position peaked at $6.46M in Q1 2014.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.